Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline
Lilly acquires Ventyx to expand oral inflammation pipeline.
Deals
Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
Ikarovec Eyes $1B Deal to Move Eye Gene Therapy In-Office
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.
Medline Raises $6.26B in 2025’s Biggest IPO
Medline has raised about $6.26B in an upsized IPO, surpassing CATL’s listing to become 2025’s largest debut.
BMS Signs $1.1B Multispecific Antibody Deal With Harbour
Bristol Myers Squibb has entered a global collaboration with Harbour BioMed worth up to $1.1B to discover and develop next-generation multispecific antibodies, strengthening its early-stage immunology and oncology pipeline.
Genentech Strikes $1.1B Cancer AI Deal With Caris
Genentech has signed a multi-year oncology collaboration with Caris Life Sciences worth up to $1.1B, tapping the techbio’s AI-driven tumor database to discover new solid-tumor targets as year-end dealmaking accelerates.